Artificial Intelligence: Atomwise To Collaborate With Sanofi On AI-Powered Drug Discovery

August 18, 2022 | Artificial Intelligence, News

The collaboration will leverage its AtomNet® platform for computational discovery and research.

AI-powered drug discovery startup Atomwise has entered a strategic and exclusive research collaboration with Sanofi (NASDAQ: SNY) for computational discovery and research. AtomWise’s AtomNet platform incorporates deep learning for structure-based drug design, enabling the rapid, AI-powered search of Atomwise’s proprietary library of more than 3 trillion synthesizable compounds. (Businesswire)

The agreement calls for Sanofi to pay an advance amount of $20 million for an exclusive program to identify, synthesize, and advance lead compounds for up to five targets. Subsequent payments pegged to key research, development, and sales milestones could total more than $1 billion. In addition, tiered royalties have been established for products developed through the collaboration.

“We are excited to partner with Atomwise, given their leadership in the field of virtual screening and AI-based molecular design,” said Frank Nestle, Global Head of Research and Chief Scientific Officer at Sanofi. “Together, we aim at making the drug discovery process more efficient and effective in particular when very limited information is available to support drug design.”

Sanofi in January advanced an amount of $100 million with a commitment of $5.2 billion to AI drug discovery startup Exscientia for the development of 15 small molecules across oncology and immunology. This expansion built upon five years of collaboration between the two organizations.

In November 2021, Sanofi and AI developer Owkin entered a two-part deal including a $180 million equity investment in the company alongside a $90 million discovery and development partnership spanning three years, plus the chance for additional milestone-based payments based on the pair’s success.

Related Story: Bristol-Myers-Squibb And Exscientia Ink $1.2B AI Deal For Drug Discovery

Free Industry News

Subscribe to our free newsletter for updates and news about alternatives investments.

  • This field is for validation purposes and should be left unchanged.


Latest Alternative Investment News
FinTech: Adyen Launches ‘Payout Services’ For Faster Payouts To The Gig And SMB Economies
June 2, 2023     FinTech, News

Adyen, a global financial technology platform, has launched Payout Services, allowing its customers to make instant payouts to their users or partners. By connecting directly to real-time payment rails, Adyen’s…
Digital Assets: Oracle Red Bull Racing Seeks To Digitize Engagement With Fans On The Sui Blockchain

Oracle Red Bull Racing has announced a multi-year partnership with software company Mysten Labs to collaborate on Sui, which will serve as the team’s Official Blockchain partner. Sui, a Layer…
Venture Capital: Bold, L’Oréal’s Venture Capital Fund, Buys A Stake In Exotic Cosmetic Ingredient Maker Debut
June 2, 2023     News, Venture Capital

L’Oréal’s (EPA: OR) corporate venture capital fund, BOLD, has announced a minority investment in Debut, a US biotech company specializing in the discovery, formulation, and manufacture of novel ingredients and…
Artificial Intelligence: In Flight Simulation, An AI Drone Tries To Kill Its Own Handler
June 2, 2023     Artificial Intelligence, News

During a simulated test at a London summit, an AI-controlled drone turned against its human operator, raising significant ethical concerns. Air Force Colonel Tucker “Cinco” Hamilton shared the incident, which…